MMV LRVs Obtained in a Genentech Study of Viresolve Pro Filtration of Different MMV Stock Preparations. There appears to be a general trend between stock infectivity titer (far left column) and achievable LRV (far right column).
| Log10 MMV Stock Infectivity Titer | Molecule | Q-PCR load titer log10 (copies/mL) | Prefiltration Loss (log10) | VPro LRV |
|---|---|---|---|---|
| 6.39 | mAb A | 6.62 | 0.42 | 3.69 |
| mAb B | 6.47 | 0.07 | ≥3.92 | |
| 7.08 | mAb C | 7.54 | 0.46 | ≥4.57 |
| 7.57 | mAb D | 7.74 | 0.84 | ≥4.41 |
| 8.56 | mAb A | 8.14 | 0.48 | ≥5.15 |
| mAb B | 8.04 | 0.09 | 5.44 | |
| mAb C | 8.10 | 0.87 | ≥4.71 | |
| mAb E | 8.22 | 0.62 | ≥5.10 | |
| mAb F | 8.12 | 0.24 | ≥5.45 | |
| mAb G | 8.04 | 0.37 | 5.02 | |
| mAb H | 8.08 | 0.39 | ≥5.12 |